Seminars in Oncology
Volume 35, Issue 5 , Pages 530-544 , October 2008

North Central Cancer Treatment Group—Achievements and Perspectives

References 

  1. Ingle JN, Everson LK, Wieand HS, et al. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1988;6:1388–1396
  2. Witzig TE, Gonchoroff NJ, Therneau T, et al. DNA content flow cytometry as a prognostic factor for node-positive breast cancer (The role of multiparameter ploidy analysis and specimen sonication). Cancer. 1991;68:1781–1788
  3. Witzig TE, Ingle JN, Cha SS, et al. DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer. 1994;74:1752–1761
  4. Witzig TE, Ingle JN, Schaid DJ, et al. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. J Clin Oncol. 1993;11:351–359
  5. Cunningham JM, Ingle JN, Jung SH, et al. p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J Natl Cancer Inst. 1994;86:1871–1873
  6. Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer (Results from a randomized adjuvant treatment protocol). Cancer. 1994;74:2956–2963
  7. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. [abstract] Am Soc Clin Oncol Meeting Abstracts. 2007;25(Suppl):512
  8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  9. Perez EA, Suman VJ, Davidson NE, et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol. 2004;22:3700–3704
  10. Halyard MY, Pisansky TM, Solin LJ, et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group phase III trial N9831. [abstract] Am Soc Clin Oncol Meeting Abstracts. 2006;24(Suppl):523
  11. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–3038
  12. Grant C, Hartmann L, Suman V, et al. Menstrual cycle and surgical treatment of breast cancer: Findings from the NCCTG N9431 study. Breast Cancer Res Treat. 2004;88(Suppl 1):S213
  13. Goetz M, Perez E, Suman V, et al. Association between polymorphisms in the DNA repair genes XPD and XRCC1 and clinical outcome in women treated prospectively with docetaxel and carboplatin as first-line therapy for metastatic breast cancer. [abstract 510] Proc Am Soc Clin Oncol. 2003;22:127
  14. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312–9318
  15. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113–121
  16. Goetz M, Suman VJ, Ingle JN, et al. A two-gene expression ratio of HOXB13 and IL-17BR for predication of recurrence and survival in women receiving adjuvant tamoxifen. [abstract 312] Breast Cancer Res Treat. 2005;100(Suppl 1):S53
  17. Ingle JN, Green SJ, Ahmann DL, et al. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol. 1986;4:958–964
  18. Ingle JN, Krook JE, Green SJ, et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol. 1986;4:178–185
  19. Buckner JC, Ingle JN, Everson LK, et al. Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. Breast Cancer Res Treat. 1989;13:135–142
  20. Ingle JN, Foley JF, Mailliard JA, et al. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer. 1994;73:2337–2343
  21. Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88:124–131
  22. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005;6:425–432
  23. Perez EA, Hillman DW, Mailliard JA, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22:2849–2855
  24. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358
  25. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8678
  26. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl Med. 1994;331:502–507
  27. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl Med. 2003;349:247–257
  28. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997;15:2910–2919
  29. Goldberg RM, Sargent D, Morton RF, et al. N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study. [abstract 3621] Proc Am Soc Clin Oncol. 2004;23:275
  30. Goldberg RM, McLeod HL, Sargent DJ, et al. Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. American Society of Clinical Oncology Meeting Abstracts. 2006;24(Suppl):3503
  31. McLeod HL, Parodi L, Sargent DJ, et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from trial N9741. American Society of Clinical Oncology Meeting Abstracts. 2006;24(Suppl):3520
  32. Grothey A, McLeod HL, Green EM, et al. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. American Society of Clinical Oncology Meeting Abstracts. 2005;23(Suppl):3509
  33. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–1214
  34. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–4091
  35. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243–9249
  36. Alberts SR, Mahoney MR, Donohue J, et al. Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver: a North Central Cancer Treatment Group (NCCTG) phase II intergroup trial. American Society of Clinical Oncology Meeting Abstracts. 2006;24(Suppl):3525
  37. The Clinical Outcomes of Surgical Therapy Study Group (COST). A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–2059
  38. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–328
  39. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma (Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin). Cancer. 1990;65:2207–2212
  40. Kim GP, Oberg AL, Foster NR, et al. Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. American Society of Clinical Oncology Meeting Abstracts. 2007;25(Suppl):4553
  41. Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer (North Central Cancer Treatment Group). J Clin Oncol. 1994;12:412–416
  42. Mandrekar SJ, Northfelt DW, Schild SE, et al. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol. 2006;1:556–563
  43. Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer (Pooled analysis of North Central Cancer Treatment Group trials). Cancer. 2006;107:781–792
  44. Schild SE, Stella PJ, Geyer SM, et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biology Phys. 2002;54:370–378
  45. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201–3206
  46. Schild SE, Mandrekar SJ, Jatoi A, et al. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer. 2007;110:363–368
  47. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? (Results of a pooled analysis from the North Central Cancer Treatment Group). J Clin Oncol. 2005;23:9113–9119
  48. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:943–951
  49. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267–2276
  50. Buckner JC, Gesme D, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251–255
  51. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol. 2005;23:5294–5304
  52. Galanis E, Jaeckle KA, Maurer MJ, et al. N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). American Society of Clinical Oncology Meeting Abstracts. 2007;25(Suppl):2004
  53. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006;65:1192–1199
  54. Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery. 2005;57:495–504
  55. Laack NN, Brown PD, Ivnik RJ, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys. 2005;63:1175–1183
  56. Brown PD, Buckner JC, O'Fallon JR, et al. Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys. 2004;59:117–125
  57. Brown PD, Jensen AW, Felten SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24:5427–5433
  58. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852–9861
  59. Jaeckle KA, Decker PA, Ballman KV, et al. Analysis of paired glioma tissues from initial diagnosis and recurrence in patients enrolled on NCCTG clinical trials: de-differentiation and association with survival. American Society of Clinical Oncology Meeting Abstracts. 2006;24(Suppl):1521
  60. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neurooncology. 2007;9:29–38
  61. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neurooncology. 2006;8:156–165
  62. Loprinzi CL, Barton DL, Jatoi A, et al. Symptom control trials: a 20-year experience. J Support Oncol. 2007;5:119–125
  63. Fidler P, Loprinzi CL, O'Fallon JR, et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer. 1996;77:522–525
  64. Foote RL, Loprinzi CL, Frank AR, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol. 1994;12:2630–2633
  65. Kozelsky TF, Meyers GE, Sloan JA, et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol. 2003;21:1669–1674
  66. Loprinzi CL, Cianflone SG, Dose AM, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer. 1990;65:1879–1882
  67. Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:1235–1238
  68. Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9:449–452
  69. Martenson J, Hyland G, Moertel CG, et al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys. 1996;35:299–303
  70. Martenson JA, Bollinger JW, Sloan JA, et al. Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: a North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. J Clin Oncol. 2000;18:1239–1245
  71. Martenson JA, Sloan J, Deming RL, et al. Phase III double-blind study of depot octreotide vs. placebo in the prevention of acute diarrhea during pelvic radiation therapy: results of North Central Cancer Treatment Group protocol N00CA. Am Soc Clin Oncol. Meeting Abstracts. 2006;25(Suppl):8506
  72. McGinnis WL, Loprinzi CL, Buskirk SJ, et al. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol. 1999;4:328–332
  73. Okuno SH, Foote RL, Loprinzi CL, et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer. 1997;79:2193–2199
  74. Okuno SH, Foote RL, Olmscheid MA, et al. Evaluation of an oral capsaicin lozenge for preventing radiation-induced mucositis. J Cancer Integrative Med. 2004;2:179–183
  75. Okuno SH, Woodhouse CO, Loprinzi CL, et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol. 1999;22:258–261
  76. Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc. 2005;97:1161–1164
  77. Karagozoglu S, Filiz Ulusoy M. Chemotherapy: the effect of oral cryotherapy on the development of mucositis. J Clin Nurs. 2005;14:754–765
  78. Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs. 2005;14:750–753
  79. Papadeas E, Naxakis S, Riga M, Kalofonos C. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. Eur J Oncol Nurs. 2007;11:60–65
  80. Dreicer R, Propert KJ, Kuzel T, et al. A phase II trial of edatrexate in patients with advanced renal cell carcinoma (An Eastern Cooperative Oncology Group study). Am J Clin Oncol. 1997;20:251–253
  81. Edelman MJ, Gandara DR, Perez EA, et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs. 1998;16:69–75
  82. Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol. 1997;41:75–78
  83. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(Suppl):2026–2046
  84. Aisa Y, Mori T, Kudo M, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2005;13:266–269
  85. Dumontet C, Sonnet A, Bastion Y, et al. Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant. 1994;14:492–494
  86. Inagaki N, Ohue Y, Shigeta H, Tasaka T. Cryotherapy is useful and safe in the prevention of oral mucositis after high-dose melphalan (L-PAM). Rinsho Ketsueki. 2006;47:1469–1471
  87. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37:1031–1035
  88. Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F. Ice pops to prevent melphalan-induced stomatitis. Lancet. 1996;347:1691–1692
  89. Mori T, Yamazaki R, Aisa Y, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2006;14:392–395
  90. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? (A randomized, double-blind, placebo-controlled trial). J Clin Oncol. 1995;13:2856–2859
  91. Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J Clin Oncol. 2000;18:2930–2932
  92. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469–2476
  93. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567–573
  94. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990;65:2657–2662
  95. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82:1127–1132
  96. Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994;12:1126–1129
  97. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17:3299–3306
  98. Loprinzi CL, Kuross SA, O'Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol. 1994;12:1121–1125
  99. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol. 1993;11:762–767
  100. Rowland KM, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996;14:135–141
  101. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16:495–500
  102. Loprinzi CL, Khoyratty BS, Dueck AC, et al. Gabapentin for hot flashes in men: NCCTG trial N00CB [abstract 9005]. J Clin Oncol. 2007;25(Suppl):494S
  103. Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007;25:308–312
  104. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059–2063
  105. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group trial N99C7. J Clin Oncol. 2006;24:1409–1414
  106. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347–352
  107. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578–1583
  108. Pockaj BA, Gallagher J, Loprinzi CL, et al. A phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC. J Clin Oncol. 2006;24:2836–2841
  109. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol. 2000;18:1068–1074
  110. Sloan JA, Loprinzi CL, Novotny PJ, et al. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001;19:4280–4290
  111. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12:155–158
  112. Loprinzi CL, Goldberg RM, O'Fallon JR, et al. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol. 1994;151:634–636
  113. Halyard MY, Frost MH, Dueck A. Integrating QOL assessments for clinical and research purposes. Curr Problems Cancer. 2006;30:319–330
  114. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001;57(Suppl 1):205–212
  115. Sloan JA, Loprinzi CL, Laurine JA, et al. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol. 2001;19:3539–3546
  116. Sloan JA, Varricchio C. Quality of life endpoints in prostate chemoprevention trials. Urology. 2001;57(Suppl 1):235–240
  117. Hampton T. Patients' genes may influence quality of life after cancer chemotherapy. JAMA. 2004;292:673–674
  118. Sloan JA, Zhao CX. Genetics and quality of life. Curr Problems Cancer. 2006;30:255–260
  119. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharmaceutical Stat. 2004;14:73–96
  120. Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA. A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials. Cancer. 2007;109:787–795
  121. Mandrekar S, Dueck A. Future directions in QOL research. Curr Problems Cancer. 2005;29:343–351
  122. Cella D, Bullinger M, Scott C, Barofsky I. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc. 2002;77:384–392
  123. Frost MH, Bonomi AE, Ferrans CE, Wong GY, Hays RD. Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores. Mayo Clin Proc. 2002;77:488–494
  124. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371–383
  125. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479–487
  126. Sloan JA, Cella D, Frost M, et al. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc. 2002;77:367–370
  127. Symonds T, Berzon R, Marquis P, Rummans TA. The clinical significance of quality-of-life results: practical considerations for specific audiences. Mayo Clin Proc. 2002;77:572–583
  128. Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res. 2005;14:285–295
  129. Sloan JA, Frost MH, Berzon R, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14:988–998
  130. Sloan JA. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. COPD. 2005;2:57–62
  131. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005;58:1217–1219
  132. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16:3662–3673
  133. Varricchio CG, Sloan JA. The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst. 2002;94:1184–1185
  134. Buchanan DR, White JD, O'Mara AM, et al. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience. J Clin Oncol. 2005;23:6682–6689
  135. Morton RF, Sloan JA, Grothey A, et al. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. American Society of Clinical Oncology Meeting Abstracts. 2005;23(Suppl):8087
  136. Hobday TJ, Kugler JW, Mahoney MR, et al. Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol. 2002;20:4574–4580
  137. Meyerhardt JA, Sloan JA, Sargent DJ, et al. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1402–1410
  138. Sargent DJ, Goldberg RM, Mahoney MR, et al. Rapid reporting and review of an increased incidence of a known adverse event. J Natl Cancer Inst. 2000;92:1011–1013
  139. Goldberg RM, Sargent DJ, Morton RF, et al. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group’s real-time toxicity monitoring program. J Clin Oncol. 2002;20:4591–4596
  140. Mahoney MR, Sargent DJ, O’Connell MJ, et al. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol. 2005;23:9275–9281
  141. Hillman S, Sargent DJ, An M, et al. Evaluation of RECIST criteria in determining the response to treatment in solid tumors: a North Central Cancer Treatment Group (NCCTG) investigation. [abstract 2095] Proc Am Soc Clin Oncol. 2003;22:
  142. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25:4569–4574
  143. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664–8670
  144. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–526
  145. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556
  146. Therneau TM. How many stratification factors are “too many” to use in a randomization plan?. Controlled Clin Trials. 1993;14:98–108
  147. Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics. 1995;51:1469–1482
  148. Sargent DJ, Goldberg RM. A flexible design for multiple armed screening trials. Stat Med. 2001;20:1051–1060

PII: S0093-7754(08)00169-3

doi: 10.1053/j.seminoncol.2008.07.006

Seminars in Oncology
Volume 35, Issue 5 , Pages 530-544 , October 2008

Article Tools

* Image Usage & Resolution